Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

Study:

Phase III, Open-Label, Multicenter International Study to Evaluate the Efficacy and Safety of an Octreotide Implant vs. Sandostatin LAR Depot in Patients With Acromegaly

Rationale:

n/a

Purpose:

Evaluate the efficacy, safety and tolerability of the octreotide implant in patients with acromegaly that were previously treated with octreotide depot.

Study Status: Terminated

Recruiting:
n/a

Condition Intervention Phase
Acromegaly Drug: Octreotide Implant
Drug: Sandostatin LAR Depot
Phase 3

Verified by Endo Pharmaceuticals September, 2013

Sponsored by: Endo Pharmaceuticals
Information provided by: Endo Pharmaceuticals
ClinicalTrials.gov identifier: NCT00765323

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

The Cleveland Clinic
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site